Yuan M, Huang L-L, Chen J-H, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.

Article  PubMed  PubMed Central  Google Scholar 

Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959–69.

Article  CAS  PubMed  Google Scholar 

Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv. 2022;6:307–20.

Article  PubMed  PubMed Central  Google Scholar 

Riaz IB, Fuentes H, Deng Y, Naqvi SAA, Yao X, Sangaralingham LR, et al. Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis. JAMA Netw Open. 2023;6:e2325283–e.

Article  PubMed  PubMed Central  Google Scholar 

Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329:1924–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New Engl J Med. 2018;378:615–24.

Article  CAS  PubMed  Google Scholar 

Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. New Engl J Med. 2020;382:1599–607.

Article  CAS  PubMed  Google Scholar 

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18:411–21.

Article  CAS  PubMed  Google Scholar 

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017–23.

Article  CAS  PubMed  Google Scholar 

Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23:e334–e47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizos T, Meid AD, Huppertz A, Dumschat C, Purrucker J, Foerster KI, et al. Low exposure to direct oral anticoagulants is associated with ischemic stroke and its severity. J Stroke. 2022;24:88–97.

Article  PubMed  PubMed Central  Google Scholar 

Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol. 2014;63:321–8.

Article  CAS  PubMed  Google Scholar 

Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385:2288–95.

Article  CAS  PubMed  Google Scholar 

Otten LS, Piet B, van den Heuvel MM, Marzolini C, van Geel R, Gulikers JL, et al. Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer. Eur Respir Rev. 2022;31.

Van der Linden L, Vanassche T, Van Cutsem E, Van Aelst L, Verhamme P. Pharmacokinetic drug–drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. Br J Clin Pharmacol. 2023;89:2369–76.

Article  PubMed  Google Scholar 

Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug–drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost. 2023.

UpToDate. Inhibitors and inducers of P-glycoprotein (P-gp) drug efflux pump (p-gp multidrug resistance transporter). https://www.uptodate.com/contents/image/print?imageKey=EM%2F73326&topicKey=HEME%2F1370&source=see_link.

UpToDate. Cytochrome P450 3A (including 3A4) inhibitors and inducers. https://www.uptodate.com/contents/image?imageKey=CARD%2F76992.

Kennisbank K Interactielijsten: KNMP. https://kennisbank.knmp.nl/article/Informatorium_Medicamentorum/G1126.html#G2055.

Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:1308–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Specialisten FM. Antitrombotisch beleid: Federatie Medisch specialisten; 2020 [updated 24-3-2021. https://richtlijnendatabase.nl/richtlijn/antitrombotisch_beleid/periprocedureel_beleid_bij_antistolling.html.

Gulpen AJW, Ten Cate H, Henskens YMC, van Oerle R, Wetzels R, Schalla S, et al. The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study. PLoS ONE. 2019;14:e0217302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Veelen A, van Geel R, de Beer Y, Dingemans AM, Stolk L, Ter Heine R, et al. Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results. Biomed Chromatogr. 2020;34:e4771.

Article  PubMed  Google Scholar 

van Veelen A, van Geel R, Schoufs R, de Beer Y, Stolk LM, Hendriks LEL, et al. Development and validation of an HPLC–MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. Biomed Chromatogr. 2021;35:e5224.

Article  PubMed  Google Scholar 

Gulikers JL, van Veelen AJ, Sinkiewicz EMJ, de Beer YM, Slikkerveer M, Stolk LML, et al. Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma. Biomed Chromatogr. 2023;37:e5628.

Article  CAS  PubMed  Google Scholar 

Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit. 2009;31:579–84.

Article  CAS  PubMed  Google Scholar 

van Veelen A, Veerman GDM, Verschueren MV, Gulikers JL, Steendam CMJ, Brouns A, et al. Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer. Int J Cancer. 2023;154:332–42.

Chen J, Houk B, Pithavala YK, Ruiz-Garcia A. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants. CPT Pharmacomet Syst Pharm. 2021;10:148–60.

Article  Google Scholar 

Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH, et al. Exposure-response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non-small cell lung cancer patients. Clin Pharm Ther. 2021;109:394–402.

Article  CAS  Google Scholar 

Moreno V, Greil R, Yachnin J, Majem M, Wermke M, Arkenau H-T, et al. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. Clin Ther. 2021;43:1092–111.

Article  CAS  PubMed  Google Scholar 

Wickham H. ggplot2: elegant graphics for data analysis. Springer-Verlag New York; 2016 [Available from: https://ggplot2.tidyverse.org].

Wilke CO. cowplot: streamlined plot theme and plot annotations for ‘ggplot2’; 2020 [Available from: https://wilkelab.org/cowplot]

Wickham H. forcats: tools for working with categorical variables (factors); 2023 [Available from: https://forcats.tidyvers.org]

Team R. RStudio: Integrated Development for R.: RStudio, Inc., Boston, MA; 2016 [Available from: http://www.rstudio.com/].

Cary N SAS version 9.4. USA: Inc. SI.; 2016.

Bolek H, Ürün Y. Cancer-associated thrombosis and drug-drug interactions of antithrombotic and antineoplastic agents. Cancer. 2023;129:3216–29.

Toorop MMA, van Rein N, Nierman MC, Vermaas HW, Huisman MV, van der Meer FJM, et al. Inter- and intra-individual concentrations of direct oral anticoagulants: the KIDOAC study. J Thromb Haemost. 2022;20:92–103.

Article  CAS  PubMed  Google Scholar 

Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res. 2016;137:178–83.

Article  CAS  PubMed  Google Scholar 

Bernier M, Lancrerot SL, Parassol N, Lavrut T, Viotti J, Rocher F, et al. Therapeutic drug monitoring of direct oral anticoagulants may increase their benefit-risk ratio. J Cardiovasc Pharmacol. 2020;76:472–7.

Article  CAS  PubMed  Google Scholar 

Jelliffe R, Christians U. The new direct-acting oral anticoagulants need to be monitored! Ther Drug Monit. 2020;42:357–9.